童流妹,徐惠亮,蒋红良

• 1:绍兴第二医院肿瘤内科

摘要(Abstract)：

目的比较SOX方案(替吉奥联合奥沙利铂)和XELOX方案(卡培他滨联合奥沙利铂)一线治疗晚期胃癌近期疗效、远期疗效及化疗不良反应。方法 62例晚期胃癌患者随机分为SOX组(n=32)和XELOX组(n=30),两组均接受>2周期的化疗,每2周期后评价近期疗效,观察化疗相关不良反应。结果 SOX组有效率、疾病控制率、中位疾病进展时间、中位生存时间分别为43.8%、81.3%、6.2月、11.6月;XELOX组有效率、疾病控制率、中位疾病进展时间、中位生存时间分别为33.3%、73.3%、6.0月、10.9月,两组有效率及生存期比较差异均无统计学意义(均P>0.05)。两组Ⅲ~Ⅳ级血液学毒性方面差异无统计学意义(P>0.05),非血液学毒性方面外周神经毒性及手足综合征发生率XELOX组高于SOX组(均P<0.05)。结论 SOX及XELOX方案一线治疗晚期胃癌疗效均较高,疗效相近,不良反应均可耐受,XELOX组在外周神经症状及手足综合征方面发生率较SOX组高。

关键词(KeyWords)： 胃肿瘤/药物疗法;脱氧胞苷/治疗应用;脱氧胞苷/类似物和衍生物;有机铂化合物/治疗应用;氟尿嘧啶/治疗应用;氟尿嘧啶/类似物和衍生物;抗肿瘤联合化疗方案/治疗应用;存活率;治疗结果

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 童流妹,徐惠亮,蒋红良

DOI: 10.13267/j.cnki.syzlzz.2015.01.015

参考文献(References)：

• [1]Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
• [2]NCI.CTCAE[EB/OL].(2010-05-17)[2014-06-20].http://evs.nci.nih.gov/ftp1/CTCAE/About.html.
• [3]徐瑞华,腾开原.晚期胃癌化疗进展[J].癌症,2009,28(10):1108-1113.
• [4]Koizumi W,Takiuchi H,Yamada Y,et al.PhaseⅡstudy of oxaliplatin plus S-1 as first-line treatment for advance gastric cancer[J].Ann Oncol,2010,21(5):1001-1005.
• [5]Park I,Lee JL,Ryu MH,et al.PhaseⅠ/Ⅱand pharmacokinetic study of S-1 and oxaliplatinin previously untreated advance gastric cancer[J].Cancer Chemother Pharmacol,2010,65(3):473-480.
• [6]Liu B,Ying J,Luo C,et al.S-1 combined with oxaliplatinas first line chemotherapy for chinese advanced gastriccancer patients[J].Hepatogastroenterology,2012,34(114):649-653.
• [7]Bang YJ,Kim YW,Yan HK,et al.Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectony(GLASSIC)a phase 3 open-label randomized controlled trial[J].Lancet,2012,79(9813):315-321.
• [8]Quek R,Lim WT,Foo KF,et al.Capcitabine and oxaliplatin(XELOX)in the treatment of advanced gastric cancer[J].Acta Oncol,2007,46(8):1032-1034.
• [9]Park YH,Lee JL,Ryoo BY,et al.Capcitabine in combination with oxaliplatin(XELOX)as a first-line therapy for advanced gastric cancer[J].Chemother Pharmacol,2008,61(4):623-629.
• [10]Yang T,Shen X,Tang X,et al.PhaseⅡtrial of oxaliplatin plus oral capecitabine as first-line chemotherapy for patients with advanced gastriccancer[J].Tumori,2011,18(4):466-472.
• [11]Kim GM,Jeung HC,Rha SY,et al.A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer[J].Eur J Cancer,2012,48(4):518-526.